Delcath Systems Inc. (NASDAQ: DCTH) has dosed the first patient in its Phase 2 clinical trial evaluating HEPZATO in people with liver-dominant metastatic breast cancer…
July 09, 2026
July 08, 2026
Vanda Pharmaceuticals Wins FDA Rare Pediatric Disease Status For Ultra-Rare Nerve Disorder Drug
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) has received Rare Pediatric Disease Designation from the U.S. Food and Drug Administration for VCA‑894A, an investigational antisense therapy aimed…
Clearmind Medicine Inc. (Nasdaq: CMND) is taking a meaningful step toward turning its lead compound MEAI into a nasal spray treatment for alcohol use disorder…
July 02, 2026
Artiva’s Off-the-Shelf Answer to Autoimmune CAR-T
The excitement in autoimmune disease right now runs through cell therapy. Researchers have shown that clearing a patient’s B cells can drive long remissions in…
Biogen (NASDAQ: BIIB) is using AAIC 2026 to showcase the depth of its Alzheimer’s portfolio, including new Phase 2 data for its tau‑targeting antisense drug…
World Vitiligo Day 2026 carries the theme “Look How Far We’ve Come: A Journey of Resilience, Strength, and Beauty,” marking a decade of progress for…
Passage Bio (NASDAQ: PASG) is handing the keys to Remix Therapeutics in an all‑stock reverse merger that will take Remix public, rebrand the combined company…
Helus Pharma, operating under Cybin (HELP), reported that enrollment in its APPROACH Phase 3 trial of HLP003 for major depressive disorder (MDD) is progressing as…
June 23, 2026
Quoin Pharmaceuticals Secures FDA Conditional Approval of QYLEKI™ Brand Name for QRX003
Another step in preparing QRX003 for potential commercialization Quoin Pharmaceuticals (NASDAQ: QNRX) has received FDA conditional approval of QYLEKI™ as the proposed brand name for…
June 22, 2026
BridgeBio’s Oral Infigratinib Shows Strong Phase 3 Growth Data in Children With Achondroplasia
BridgeBio Pharma Inc. (NASDAQ: BBIO) announced Phase 3 data for its oral achondroplasia therapy infigratinib from the PROPEL 3 trial at ICCBH 2026, putting a…
uniQure N.V. (NASDAQ: QURE) is rallying after the U.S. Food and Drug Administration agreed to an accelerated‑approval pathway for its Huntington’s disease gene therapy, AMT‑130,…
RedHill Biopharma’s (NASDAQ: RDHL) oral drug candidate opaganib has received Rare Pediatric Disease (RPD) designation from the U.S. Food and Drug Administration for the treatment…